
UB026
TargetsATR x mTOR
IndicationsMalignant melanoma; Oesophageal cancer; Colorectal cancer
ClinicalCN - I
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- **Market Entry Timing**: Targeting the patent expiry (LOE) window of the originator in key markets, positioning as a high-potential 'First Wave Generic' project, utilizing the NewCo structure for flexible commercial partnerships to capture early market share.
- **Ultimate Cost Competitiveness**: Leveraging China's strong upstream chemical infrastructure and API+FDF vertical integration to offer highly competitive supply prices, meeting the urgent cost-containment needs of global payers.
- **International Compliance Standards**: Emphasizing that product development follows ICH guidelines, with CMC data packages and quality systems ready for registration (ANDA/MA) in regulated markets (US/EU), minimizing regulatory risks for overseas clients.
Asset Materials

我们能如何帮助您?
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →